Company research
Viridian Therapeutics, Inc.\DE
CIK 1590750Updated Oct 6, 2026
SecurityVRDN · NASDAQ · equity
Name history
MIRAGEN THERAPEUTICS, INC. · through Jan 15, 2021SIGNAL GENETICS, INC. · through Feb 10, 2017SIGNAL GENETICS LLC · through Jul 9, 2014
VRDN price & chart
Loading TradingView…
NASDAQ:VRDN on TradingView ↗About the company
Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes. With an immediate focus in thyroid eye disease (TED), we developed Lumvoa, a full IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.
In the news
Recent filings
SCHEDULE 13G - filed by Point72 Asset Management, L.P. regarding Viridian Therapeutics, Inc.\DE
144 filing
SCHEDULE 13G/A - filed by Kynam Capital Management, LP regarding Viridian Therapeutics, Inc.\DE
SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding Viridian Therapeutics, Inc.\DE
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
4 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 577,138,000Source | 771,900,000Source | 1,097,233,000Source | 582,324,000Source | 585,663,000Source | 789,017,000Source | 660,981,000Source | 630,381,000Source | 899,418,000Source | 742,403,000Source | 490,424,000Source | 435,091,000Source |
| Property, Plant and Equipment, NetUSD | 1,125,000Source | 1,290,000Source | 2,765,000Source | 1,091,000Source | 1,514,000Source | 1,130,000Source | 1,162,000Source | 1,526,000Source | 1,228,000Source | 1,236,000Source | 1,672,000Source | 1,326,000Source |
| Current assets: | ||||||||||||
| Assets, CurrentUSD | 571,913,000Source | 767,357,000Source | 1,081,270,000Source | 578,750,000Source | 581,664,000Source | 784,744,000Source | 657,238,000Source | 626,818,000Source | 894,233,000Source | 738,461,000Source | 486,478,000Source | 431,173,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 11,012,000Source | 14,103,000Source | 24,740,000Source | 15,394,000Source | 10,298,000Source | 22,563,000Source | 20,605,000Source | 13,529,000Source | 19,581,000Source | 20,877,000Source | 9,006,000Source | 6,521,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,582,000Source | 2,400,000Source | 2,085,000Source | 1,977,000Source | 1,826,000Source | 2,255,000Source | 2,092,000Source | 1,482,000Source | 2,421,000Source | 2,205,000Source | 1,670,000Source | 1,610,000Source |
| Other Assets, NoncurrentUSD | 1,518,000Source | 853,000Source | 1,113,000Source | 506,000Source | 659,000Source | 888,000Source | 489,000Source | 555,000Source | 1,536,000Source | 501,000Source | 604,000Source | 982,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 74,168,000Source | 64,404,000Source | 435,136,000Source | 67,155,000Source | 56,325,000Source | 153,009,000Source | 56,508,000Source | 47,851,000Source | 177,251,000Source | 70,764,000Source | 48,402,000Source | 40,027,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 822,000Source | 792,000Source | 1,132,000Source | 817,000Source | 639,000Source | 1,025,000Source | 816,000Source | 638,000Source | 1,018,000Source | 810,000Source | 540,000Source | 414,000Source |
| Additional Paid in CapitalUSD | 1,531,003,000Source | 1,433,019,000Source | 2,134,572,000Source | 1,508,902,000Source | 1,168,975,000Source | 1,946,844,000Source | 1,497,296,000Source | 1,156,999,000Source | 1,927,104,000Source | 1,477,811,000Source | 960,536,000Source | 741,067,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,218,103,000Source | -916,132,000Source | -1,570,478,000Source | -1,183,504,000Source | -839,443,000Source | -1,443,359,000Source | -1,082,769,000Source | -774,450,000Source | -1,338,458,000Source | -995,857,000Source | -725,908,000Source | -488,174,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 363,000Source | 932,000Source | -1,153,000Source | 69,000Source | -543,000Source | -558,000Source | 245,000Source | -367,000Source | 447,000Source | -10,000Source | 338,000Source | -390,000Source |
| Stockholders' Equity Attributable to ParentUSD | 502,970,000Source | 707,496,000Source | 662,097,000Source | 515,169,000Source | 529,338,000Source | 636,008,000Source | 604,473,000Source | 582,530,000Source | 722,167,000Source | 671,639,000Source | 442,022,000Source | 395,064,000Source |
| Liabilities and EquityUSD | 577,138,000Source | 771,900,000Source | 1,097,233,000Source | 582,324,000Source | 585,663,000Source | 789,017,000Source | 660,981,000Source | 630,381,000Source | 899,418,000Source | 742,403,000Source | 490,424,000Source | 435,091,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 50,696,000Source | 41,364,000Source | 63,794,000Source | 52,585,000Source | 36,762,000Source | 51,805,000Source | 33,727,000Source | 26,127,000Source | 70,696,000Source | 47,874,000Source | 26,635,000Source | 33,349,000Source |
| Operating Lease, Liability, CurrentUSD | 730,000Source | 589,000Source | 722,000Source | 553,000Source | 507,000Source | 738,000Source | 536,000Source | 732,000Source | 753,000Source | 513,000Source | 843,000Source | 613,000Source |
| Accounts Payable, CurrentUSD | 10,063,000Source | 6,338,000Source | 8,652,000Source | 8,518,000Source | 3,140,000Source | 13,313,000Source | 3,886,000Source | 2,676,000Source | 8,683,000Source | 2,143,000Source | 2,239,000Source | 14,234,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,200,000Source | 2,200,000Source | — | 1,700,000Source | 1,600,000Source | — | 1,900,000Source | 900,000Source | 1,900,000Source | 2,000,000Source | 1,000,000Source | 1,100,000Source |
| Other Liabilities, NoncurrentUSD | 2,582,000Source | 2,161,000Source | 1,851,000Source | 2,077,000Source | 1,648,000Source | 2,176,000Source | 1,884,000Source | 896,000Source | 2,341,000Source | 2,024,000Source | 989,000Source | 1,172,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 40,633,000Source | 34,738,000Source | 55,142,000Source | 35,344,000Source | 30,370,000Source | 38,492,000Source | 29,553,000Source | 23,163,000Source | 62,013,000Source | 45,443,000Source | 24,108,000Source | 18,827,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 490,900,000Source | 753,200,000Source | 981,500,000Source | 563,400,000Source | 571,400,000Source | 762,200,000Source | 636,600,000Source | 613,200,000Source | 874,700,000Source | 717,600,000Source | 477,400,000Source | 424,600,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 20,890,000Source | 20,523,000Source | — | 12,353,000Source | 17,487,000Source | — | 20,685,000Source | — | — | 20,582,000Source | — | — |
| Long-term Debt, Current Maturities | — | — | — | —Source | —Source | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 121,000Source | 117,000Source | 460,000Source | 540,000Source | 522,000Source | 255,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 13,390,000Source | 10,220,000Source | 44,303,000Source | 42,150,000Source | 67,172,000Source | 19,765,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 4,630,000Source | 1,765,000Source | 6,562,000Source | -73,000Source | -12,040,000Source | 11,524,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -119,654,000Source | -92,653,000Source | -276,391,000Source | -232,319,000Source | -184,170,000Source | -93,838,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 77,261,000Source | 100,062,000Source | -37,563,000Source | -228,651,000Source | -94,252,000Source | -115,126,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 23,000Source | 86,000Source | 495,000Source | 511,000Source | 898,000Source | 797,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 6,357,000Source | 9,212,000Source | 426,742,000Source | 457,737,000Source | 225,670,000Source | 322,244,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -36,036,000Source | 16,621,000Source | 112,788,000Source | -3,233,000Source | -52,752,000Source | 113,280,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 169,647,000Source | 200,317,000Source | 164,986,000Source | 117,324,000Source | 176,346,000Source | 116,215,000Source | 212,382,000Source | 99,594,000Source | 102,827,000Source | 155,579,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,119,000Source | 448,000Source | 2,150,000Source | 1,820,000Source | 886,000Source | 293,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 11,250,000Source | 8,720,000Source | 16,984,000Source | 10,844,000Source | 13,390,000Source | 10,220,000Source | 44,303,000Source | 42,150,000Source | 67,172,000Source | 19,765,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | 103,000Source | — | 377,000Source | 317,000Source | 228,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 490,900,000Source | 753,200,000Source | 981,500,000Source | 563,400,000Source | 762,200,000Source | 636,600,000Source | 874,700,000Source | 717,600,000Source | 477,400,000Source | 424,600,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | -1,190,000Source | 0Source | 7,530,000Source | 0Source | -700,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | -449,000Source | -1,000Source | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | -181,000Source | — |
| General and Administrative ExpenseUSD | — | — | 24,322,000Source | 14,408,000Source | — | 20,216,000Source | — | 17,103,000Source | — | 61,083,000Source | 94,999,000Source | 35,182,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 560,000Source | 529,000Source | 8,307,000Source | 514,000Source | 3,462,000Source | 550,000Source | 4,948,000Source | 3,046,000Source | — | — |
| Investment Income, InterestUSD | — | — | 5,521,000Source | 7,515,000Source | 8,490,000Source | 6,546,000Source | 7,872,000Source | 7,540,000Source | 27,399,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -34,599,000Source | -76,689,000Source | -127,119,000Source | -100,735,000Source | -104,901,000Source | -86,912,000Source | -342,601,000Source | -269,949,000Source | -237,734,000Source | -129,874,000Source |
| Nonoperating Income (Expense)USD | — | — | 5,414,000Source | 6,791,000Source | -851,000Source | 6,032,000Source | 11,268,000Source | 6,954,000Source | 20,794,000Source | 29,086,000Source | 16,716,000Source | 4,430,000Source |
| Operating ExpensesUSD | — | — | 110,583,000Source | 83,566,000Source | 126,552,000Source | 106,842,000Source | 116,310,000Source | 93,938,000Source | 434,244,000Source | 299,337,000Source | 254,764,000Source | 136,076,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 453,000Source | -195,000Source | 156,000Source | 0Source | -672,000Source | -36,000Source | -1,657,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 0Source | 4,943,000Source | 63,145,000Source | 453,660,000Source | 125,069,000Source | 291,874,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | 28,875,000Source | 0Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 6,357,000Source | 2,297,000Source | 12,053,000Source | 5,344,000Source | 19,263,000Source | 2,762,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 70,570,000Source | 86,000Source | 284,000Source | 75,000Source | 141,000Source | 72,000Source | 70,849,000Source | 302,000Source | 314,000Source | 1,772,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | -300,000Source | 700,000Source | -200,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | — | — | 54,975,000Source | 20,216,000Source | 38,679,000Source | 17,103,000Source | 95,315,000Source | — | — | — |
| Operating Income (Loss)USD | — | — | -40,013,000Source | -83,480,000Source | -126,268,000Source | -106,767,000Source | -116,169,000Source | -93,866,000Source | -363,395,000Source | -299,035,000Source | -254,450,000Source | -134,304,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -34,599,000Source | -76,689,000Source | -127,119,000Source | -100,735,000Source | -104,901,000Source | -86,912,000Source | -342,601,000Source | -269,949,000Source | -237,734,000Source | -129,874,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | -1.15Source | — | — | — | — | — | — | -5.31Source | -4.05Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | -1.15Source | — | — | — | — | — | — | -5.31Source | -4.05Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | 66,420,063Source | — | — | — | — | — | — | 44,755,475Source | 32,087,293Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | 66,420,063Source | — | 81,593,463Source | — | 81,344,134Source | — | — | 44,755,475Source | 32,087,293Source |
| Interest Expense (non-operating)USD | — | — | 560,000Source | 529,000Source | 8,307,000Source | 514,000Source | 3,462,000Source | 550,000Source | 4,948,000Source | 3,046,000Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 24,322,000Source | 14,408,000Source | — | 20,216,000Source | — | 17,103,000Source | — | 61,083,000Source | 94,999,000Source | 35,182,000Source |
| Interest and Other IncomeUSD | — | — | — | 7,795,000Source | — | 6,546,000Source | — | 7,540,000Source | — | 32,132,000Source | 18,563,000Source | 4,916,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 500,000Source |
| Investment Income, InterestUSD | — | — | 5,521,000Source | 7,515,000Source | 8,490,000Source | 6,546,000Source | 7,872,000Source | 7,540,000Source | 27,399,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 5,414,000Source | 6,791,000Source | -851,000Source | 6,032,000Source | 11,268,000Source | 6,954,000Source | 20,794,000Source | 29,086,000Source | 16,716,000Source | 4,430,000Source |
| Operating ExpensesUSD | — | — | 110,583,000Source | 83,566,000Source | 126,552,000Source | 106,842,000Source | 116,310,000Source | 93,938,000Source | 434,244,000Source | 299,337,000Source | 254,764,000Source | 136,076,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 453,000Source | -195,000Source | 156,000Source | 0Source | -672,000Source | -36,000Source | -1,657,000Source | — | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 70,570,000Source | 86,000Source | 284,000Source | 75,000Source | 141,000Source | 72,000Source | 70,849,000Source | 302,000Source | 314,000Source | 1,772,000Source |
Filing attachments
p15055971ex_99-1.htm · SCHEDULE 13G · 2026-08-20
EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗d174744dex991.htm · 8-K · 2026-08-06
EX-99.1 2 d174744dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results - Lumvoa ™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S. - - Elegrobart, potentially the first subcutaneous autoinjector for the treatment of TED, on track for BLA submission Q1 2027 - - Pipeline progress continues, wit…
Read attachment ↗d164211dex991.htm · 8-K · 2026-06-29
EX-99.1 2 d164211dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa ™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease - First approved treatment for thyroid eye disease (TED) with labeling that includes data for both active and chronic TED - - In two pivotal phase 3 clinical trials, Lumvoa treatment showed rapid, consistent, and durable reductions of the key signs and symptoms of both active and chronic TED - - Lumvo…
Read attachment ↗d154062dex41.htm · 8-K · 2026-05-11
EX-4.1 4 d154062dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 VIRIDIAN THERAPEUTICS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 11, 2026 CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02…
Read attachment ↗d154062dex42.htm · 8-K · 2026-05-11
EX-4.2 5 d154062dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 VIRIDIAN THERAPEUTICS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 11, 2026 1.75% Convertible Senior Notes due 2032 CROSS REFERENCE TABLE* Trust Indenture Indenture Section Act Section 310(a)(1) N/A (a)(2) N/A (a)(3) N/A (a)(4) …
Read attachment ↗d20977dex991.htm · 8-K · 2026-05-05
EX-99.1 2 d20977dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-2 Clinical Trial in Chronic Thyroid Eye Disease - REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved 50% and 54% proptosis responder rates (PRR) at week 24, respectively, versus 15% placebo, both highly statistically significant results (p < 0.0001) - - Elegrobart Q4W a…
Read attachment ↗